

**University of Miami/Jackson Memorial Hospital (Main)**  
**ANTIBIOTIC SUSCEPTIBILITY REPORT January - June 2015**

Data include 1<sup>st</sup> isolate from patient (JMH Central)

T.J. Cleary, PhD (305 585-7851)

| GRAM-NEGATIVE ISOLATES                   | No.  | Percent susceptible <sup>(*)</sup> |     |     |     |                     |     |     |     |    |    |     |     |     |     |
|------------------------------------------|------|------------------------------------|-----|-----|-----|---------------------|-----|-----|-----|----|----|-----|-----|-----|-----|
|                                          |      | AMS                                | TZP | CAZ | CRO | FEP <sup>(**)</sup> | ATM | ERT | MER | AN | GM | TOB | LVX | TET | SXT |
| <i>Escherichia coli</i> <sup>(***)</sup> | 1253 | 43                                 | 93  | 89  | 84  | 93(95)              | 88  | 99  | 99  | 99 | 84 | 84  | 62  | 58  | 57  |
| <i>Citrobacter freundii</i>              | 40   | /                                  | 80  | 75  | 75  | 86(95)              | 75  | 88  | 88  | 99 | 90 | 83  | 78  | 75  | 75  |
| <i>Citrobacter koseri</i>                | 36   | /                                  | 97  | 97  | 97  | 97                  | 97  | 100 | 100 | 99 | 97 | 97  | 97  | 97  | 97  |
| <i>Klebsiella pneumoniae</i>             | 424  | nd                                 | 79  | 77  | 77  | 89(92)              | 76  | 97  | 97  | 98 | 85 | 79  | 80  | 73  | 72  |
| <i>Enterobacter aerogenes</i>            | 52   | /                                  | 87  | 85  | 73  | 91(96)              | 87  | 94  | 94  | 99 | 99 | 99  | 94  | 87  | 98  |
| <i>Enterobacter cloacae</i>              | 153  | /                                  | 81  | 78  | 77  | 91(94)              | 78  | 95  | 95  | 99 | 90 | 90  | 86  | 82  | 80  |
| <i>Serratia marcescens</i>               | 73   | /                                  | nd  | 92  | 84  | 97                  | 88  | 95  | 95  | 99 | 92 | 86  | 80  | 51  | 96  |
| <i>Proteus mirabilis</i>                 | 210  | 86                                 | 99  | 98  | 97  | 98(99)              | 99  | 99  | 99  | 99 | 93 | 94  | 85  | /   | 82  |
| <i>Morganella morganii</i>               | 41   | /                                  | 93  | 85  | 85  | 95                  | 90  | 99  | 99  | 98 | 85 | 85  | 59  | /   | 49  |
| <i>Providencia stuartii</i>              | 16   | /                                  | 94  | 88  | 88  | 94                  | 94  | 94  | 94  | 99 | /  | /   | 50  | /   | 75  |
| <i>Pseudomonas aeruginosa</i>            | 310  | nd                                 | 80  | 81  | /   | 83                  | 41  | /   | 71  | 97 | 85 | 93  | 68  | /   | /   |
| <i>Acinetobacter baumannii</i>           | 88   | /                                  | 60  | 40  | /   | /                   | /   | /   | 60  | nd | 73 | 80  | 61  | 60  | /   |
| <i>Stenotrophomonas maltophilia</i>      | 99   | /                                  | /   | nd  | /   | /                   | /   | /   | /   | /  | /  | /   | 84  | /   | 85  |

AMP AMPICILLIN  
AMS AMPICILLIN/SULBACTAM  
AN AMIKACIN  
ATM AZTREONAM  
CAZ CEFTAZIDIME  
CLN CLINDAMYCIN  
CRO CEFTRIAXONE  
CTX CEFOTAXIME  
CZ CEFAZOLIN  
DAP DAPTOMYCIN  
ERT ERTAPENEM  
FEP CEFEPIME  
FOX CEFOXITIN  
GM GENTAMICIN  
LVX LEVOFLOXACIN  
LZD LINEZOLID  
MER MEROPENEM  
PEN PENICILLIN  
RIF RIFAMPIN  
OX OXACILLIN  
SXT TRIMETH/SULFA  
TET TETRACYCLINE  
TOB TOBRAMYCIN  
TZP PIPERACILLIN/TAZO  
VA VANCOMYCIN

(\* ) Clinical Laboratory Standards Institute (CLSI) M100-S25, 2015 breakpoints for antibiotic susceptibility

(\*\*) *Enterobacteriaceae*, two cefepime has two dose-dependent susceptibility breakpoints: susceptible at 1g q12 and at (2g q8)

(\*\*\*) 94% of urinary *Escherichia coli* isolates sensitive to Nitrofurantoin

( / ) slash indicates that the drug is clinically ineffective or <20% susceptible (Sanford Guide to Antimicrobial Therapy, 2015)

(nd) no antibiotic susceptibility data available

| GRAM-POSITIVE ISOLATES                          | No. | Percent susceptible <sup>(*)</sup> |       |     |       |     |    |     |     |     |     |     |     |
|-------------------------------------------------|-----|------------------------------------|-------|-----|-------|-----|----|-----|-----|-----|-----|-----|-----|
|                                                 |     | AMP                                | PEN   | OX  | CTX   | CLN | GM | LVX | RIF | TET | LZD | VA  | SXT |
| <i>Enterococcus faecalis</i>                    | 278 | 98                                 | /     | /   | /     | /   | /  | /   | /   | 18  | 100 | 95  | /   |
| <i>Enterococcus faecium</i>                     | 59  | 29                                 | /     | /   | /     | /   | /  | /   | /   | 32  | 100 | 39  | /   |
| <i>Staph aureus MRSA</i> <sup>a</sup>           | 381 | /                                  | 0     | 0   | 0     | 69  | 91 | /   | 99  | 91  | 100 | 99  | 88  |
| <i>Staph aureus MSSA</i> <sup>a</sup>           | 381 | /                                  | 0     | 100 | 100   | 77  | 98 | /   | 99  | 89  | 100 | 99  | 95  |
| <i>Staphylococcus epidermidis</i> <sup>a</sup>  | 237 | /                                  | 0     | 26  | /     | 44  | 65 | /   | 94  | 89  | 100 | 98  | 44  |
| <i>Staphylococcus haemolyticus</i> <sup>a</sup> | 43  | /                                  | 0     | 32  | /     | 62  | 79 | /   | 98  | 65  | 100 | 100 | 56  |
| <i>Staphylococcus hominis</i> <sup>a</sup>      | 37  | /                                  | 0     | 45  | /     | 49  | 99 | /   | 99  | 70  | 100 | 100 | 57  |
| <i>Streptococcus agalactiae</i>                 | 106 | 100                                | 100   | /   | 100   | 70  | /  | 97  | /   | /   | /   | 99  | /   |
| <i>Streptococcus pneumoniae</i>                 | 21  | /                                  | (b,c) | /   | (b,c) | 68  | /  | 98  | /   | /   | /   | 98  | 70  |

(a) *S. aureus* and coagulase-negative staph (CNS) resistant to oxacillin are resistant to penicillins, cephalosporins, carbapenems  
overall MRSA = 54% of all *Staphylococcus aureus* isolates

(b) for non-meningeal infections: 95% are susceptible to penicillin (MIC ≤2.0 ug/ml); similarly, 91% are susceptible to cefotaxime/ceftriaxone (MIC <1 ug/ml) using CLSI parenteral breakpoints for antibiotic susceptibility

(c) for meningeal infection: 52% are susceptible to penicillin (MIC ≤0.064 ug/ml); similarly, 81% are susceptible to cefotaxime/ceftriaxone (MIC ≤0.5 ug/ml) using CLSI parenteral breakpoints for antibiotic susceptibility